<?xml version="1.0" encoding="UTF-8"?>
<p>MTBVAC is primarily being developed to replace BCG as a priming immunization against TB. The rationale for targeting infants includes the need for an improved vaccine over BCG given the remaining burden of pediatric TB, and the opportunity to deliver vaccination to a population without prior sensitization to BCG, 
 <italic>Mtb</italic> or environmental mycobacteria, thereby avoiding potential “masking” or “blocking” effects on MTBVAC-induced protection.
</p>
